Ani Pharmaceuticals (ANIP) Net Cash Flow Growth (1y) (2011 - 2026)
Ani Pharmaceuticals (ANIP) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.01 Bn | 87.15 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.14 Bn | 20.99 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.55 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.73 Bn | 16.41 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.56 Bn | 12.14 Bn | 785.00 Mn | -1,020.00% |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn | 385.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 385.49% |
| Dec 31, 2025 | 8,844.12% |
| Sep 30, 2025 | 146.56% |
| Jun 30, 2025 | 483.31% |
| Mar 31, 2025 | -29.92% |
| Dec 31, 2024 | -99.03% |
| Sep 30, 2024 | -402.88% |
| Jun 30, 2024 | -87.75% |
| Mar 31, 2024 | -48.52% |
| Dec 31, 2023 | 448.36% |
| Sep 30, 2023 | 541.72% |
| Jun 30, 2023 | 794.64% |
| Mar 31, 2023 | 162.09% |
| Dec 31, 2022 | -109.47% |
| Sep 30, 2022 | 21.15% |
| Jun 30, 2022 | -1,567.69% |
| Mar 31, 2022 | -235.94% |
| Dec 31, 2021 | 947.41% |
| Sep 30, 2021 | 8.10% |
| Jun 30, 2021 | -111.13% |